HLA class II allele and haplotype frequencies in Iranian patients with leukemia

Iranian Journal of Allergy, Asthma and Immunology

Volumn 6, Issue 3, 2007, Pages 137-142

  Khosravi, Farideh ^a   Amirzargar, Aliakbar ^a,b   Sarafnejad, Abdolfatah ^b   Nicknam, Mohammad Hossein ^a   Alimoghadam, Kamran ^c   Dianat, Saied ^a   Solgi, Ghasem ^a   Nikbin, Behrouz ^a  

^a TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^c TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Acute myelogenous leukemia (AML); Chronic myelogenous leukemia (CML); HLA class II; Polymorphism

Indexed keywords

ACUTE GRANULOCYTIC LEUKEMIA; ARTICLE; BLOOD SAMPLING; CHRONIC MYELOID LEUKEMIA; CONTROLLED STUDY; DISEASE ASSOCIATION; DNA EXTRACTION; GENE FREQUENCY; HAPLOTYPE; HLA SYSTEM; HLA TYPING; HUMAN; IRAN; MAJOR CLINICAL STUDY;

ALLELES; HAPLOTYPES; HISTOCOMPATIBILITY ANTIGENS CLASS II; HUMANS; IRAN; LEUKEMIA, MYELOID;

EID: 35949000567     PISSN: 17351502     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (28)

1. Jemal A, Murray T, Samuels A. Cancer statistics. CA. Cancer J Clin. 2003; 53: 5-26.
2. McKenzie SB. Advances in understanding the biology and genetics of acute myelocytic leukemia. Clin Lab Sci 2005; 18(1):28-37.
3. Gilliland DG, Jordan CT, Felix CA. The Molecular Basis of Leukemia. Hematology Am Soc Hematol Educ Program 2004; 1:80-97.
4. Sandler DP. Epidemiology of acute myelogenous leukemia. Semin Oncol 1987; 14(4):359-64.
5. Pedersen-Bjergaard J, Philip P, Larsen SO, Andersson M, Daugaard G, Ersboll J, et al. Therapy-related myelodysplasia and acute myeloid leukemia. Cytogenetic characteristics of 115 consecutive cases and risk in seven cohorts of patients treated intensively for malignant diseases in the Copenhagen series. Leukemia 1993; 7(12):1975-86.
6. Byrd JC, Lawrence D, Arthur DC, Pettenati MJ, Tantravahi R, Qumsiyeh M, et al. Patients with isolated trisomy 8 in acute myeloid leukemia are not cured with cytarabine-based chemotherapy: results from Cancer and Leukemia Group B 8461. Clin Cancer Res 1998; 4(5):1235-41.
7. Kurzrock R, Kantarjian HM, Druker BJ, Talpaz M. Philadelphia chromosome-positive leukemias: from basic mechanisms to molecular therapeutics. Ann Intern Med 2003; 138(10):819-30.
8. Yasukawa M, Ohminami H, Kojima K, Inokuchi K, Nishimura Y, Fujit S. Analysis of HLA-DRB1 alleles in Japanese patients with chronic myelogenous leukemia. Am J Hematol 2000; 63(2):99-101.
9. Deininger MW, Goldman JM, Melo JV. The molecular biology of chronic myeloid leukemia. Blood 2000; 96(10):3343-56.
10. de Klein A, van Kessel AG, Grosveld G, Bartram CR, Hagemeijer A, Bootsma D, et al. A cellular oncogene is translocated to the Philadelphia chromosome in chronic myelocytic leukaemia. Nature 1982; 300(5894):765-7.
11. Selleri C, Maciejewski JP, Pane F, Luciano L, Raiola AM, Mostarda I, et al. Fas-mediated modulation of Bcr/Abl in chronic myelogenous leukemia results in differential effects on apoptosis. Blood 1998; 92(3):981-9.
12. Dausset J. The major histocompatibility complex in man. Science 1981; 213(4515):1469-74.
13. Seremetis S, Cuttner J, Winchester R. Definition of a possible genetic basis for susceptibility to acute myelogenous leukemia associated with the presence of a polymorphic Ia epitope. J Clin Invest 1985; 76(4):1391-7.
14. Gowans D, O'Sullivan A, Rollinson S, Roddam P, Groves M, Fegan C, et al. Allele and haplotype frequency at human leucocyte antigen class I/II and immunomodulatory cytokine loci in patients with myelodysplasia and acute myeloid leukaemia: in search of an autoimmune aetiology. Br J Haematol 2002; 117(3):541-5.
15. Posthuma EFM, Falkenburg JHF, Apperley JF , Gratwohl A, Hertenstein B, Schipper RF, et al. On behalf of the Chronic Leukemia Working Party of the European Blood and Marrow Transplant Registry. HLA-DR4 is associated with a diminished risk of the development of chronic myeloid leukemia (CML). Leukemia 2000; 14:859-62.
16. Yotnda P, Firat H, Garcia-Pons F, Garcia Z, Gourru G, Vernant JP, et al. Cytotoxic T cell response against the chimeric p210 BCR-ABL protein in patients with chronic myelogenous leukemia. J Clin Invest 1998; 101(10):2290-6.
17. Mundhada S, Luthra R, Cano P. Association of HLA Class I and Class II genes with bcr-abl transcripts in leukemia patients with t(9;22) (q34;q11). BMC Cancer 2004; 4:25-31.
18. Bortin MM, D'Amaro J, Bach FH, Rimm AA, van Rood JJ. HLA associations with leukemia. Blood 1987; 70:227-32.
19. Tian H, Zhou SY, Liu ZH, Fu YG, Lu FJ, Lin JH, Xu AL. Association of HLA-DPB1 alleles with chronic myelogenous leukemia in southern Chinese Hans. Zhongguo Shi Yan Xue Ye Xue Za Zhi 2003; 11(3):266-8.
20. Caruso C, Lo Campo P, Botindari C, Modica MA. HLA antigens in Sicilian patients affected by chronic myelogenous leukaemia. J Immunogenet 1987; 14(6):295-9.
21. Miller SA, Dykes DD, Polesky HF. A simple salting out procedure for extracting DNA from human nucleated cells. Nucleic Acids Res 1988; 16(3):1215.
22. Olerup O, Zetterquist H. HLA class II genes in primary sclerosing cholangitis and chronic inflammatory bowel disease: no HLA-DRw52a association in Swedish patients with sclerosing cholangitis. Gut 1992; 33(7):942-6.
23. Amirzargar A, Mytilineos J, Farjadian Sh, and Opelz G. Human Leukocyte Antigen class II allele frequencies and haplotype association in Iranian normal population. Hum Immunol 2001; 62(11):1234-8.
24. Haldane Jb. The estimation and significance of the logarithm of a ratio of frequencies. Ann Hum Genet 1956; 20(4):309-11.
25. Vasmel WL, Zijlstra M, Radaszkiewicz T, Leupers CJ, de Goede RE, Melief CJ. Major histocompatibility complex class II-regulated immunity to murine leukemia virus protects against early T- but not late B-cell lymphomas. J Virol 1988; 62(9):3156-66.
26. Ten Bosch GJ, Toornvliet AC, Friede T, Melief CJ, Leeksma OC. Recognition of peptides corresponding to the joining region of p210BCR-ABL protein by human T cells. Leukemia 1995; 9(8):1344-8.
27. Pawelec G, Max H, Halder T, Bruserud O, Merl A, da Silva P, et al. BCR/ABL leukemia oncogene fusion peptides selectively bind to certain HLA-DR alleles and can be recognized by T cells found at low frequency in the repertoire of normal donors. Blood 1996; 88(6):2118-24.
28. Oguz FS, Kalayoglu S, Sarper Diler A, Tozkir H, Sargin D, Carin M, Tevfik Dorak M. HLA System Affects the Age-at-Onset in Chronic Myeloid Leukemia. Am J Hematol 2003; 73(4): 256-62.